On Wednesday, Kroger Co (NYSE:KR)’s shares declined -0.73% to $72.93.
Kroger Co (KR) stated strong fiscal first-quarter earnings Thursday and raised its same-store sales outlook, assisted by strong demand for its organic and natural food offerings.
The grocery store operator’s Q1 profit jumped 15% to $1.25 a share. Analysts polled by Thomson Reuters predictable $1.22.
Sales edged up 0.3% to $33.1 billion, just under views for $33.3 billion. But not taking into account fuel, same-store sales climbed 5.7%, accelerating from Q4’s 5.2% gain and better than Q3’s 5.6% enhance.
The Kroger Co., together with its auxiliaries, operates as a retailer in the United States and internationally. It also manufactures and processes food for sale in its supermarkets. The company operates retail food and drug stores, multi-department stores, jewelry stores, and convenience stores. Its combination food and drug stores offer natural food and organic sections, pharmacies, general merchandise, pet centers, fresh seafood, and organic produce; multi-department stores provide general merchandise items, such as apparel, home fashion and furnishings, outdoor living, electronics, automotive products, toys, and fine jewelry; and price impact warehouse stores offer grocery, and health and beauty care items, in addition to meat, dairy, baked goods, and fresh produce items.
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS)’s shares dropped -2.14% to $0.274.
AEterna Zentaris Inc. (USA) (AEZS) declared that it has received written scientific advice from the European Medicines Agency (“EMA”) regarding the further development plan, counting the study design, for the new confirmatory Phase 3 clinical study of Macrilen™ (macimorelin) for use in evaluating adult growth hormone deficiency (“AGHD”), following a Scientific Advice Meeting that was held earlier this month. As a result of the advice, the Company believes that the confirmatory Phase 3 study that was talk about with the U.S. Food & Drug Administration (“FDA”) last March, meets the EMA’s study-design expectations.
Study design
The multinational confirmatory efficacy Phase 3 clinical study with Macrilen™ for the evaluation of AGHD will be conducted as a two-way crossover study with the insulin tolerance test as the benchmark comparator. The study population will comprise of patients with a medical history documenting risk factors for AGHD and will comprise a spectrum of patients from those with a low risk of having AGHD to those with a high risk of having the condition. The Company will submit a projected final protocol to the FDA for their review prior to commencing the confirmatory efficacy Phase 3 study. A dedicated thorough Phase 3 QT study to evaluate the effect of Macrilen™ on myocardial depolarization is predictable to be initiated in early 2016.
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women’s health. The company’s product pipeline comprises MACRILEN, which accomplished the Phase 2 trial for use in the diagnosis of adult growth hormone deficiency; and zoptarelin doxorubicin, which is in Phase 3 clinical study zoptarelin doxorubicin in endometrial cancer (ZoptEC) of the compound in women with advanced, recurrent, or metastatic endometrial cancer.
At the end of Wednesday’s trade, Macy’s, Inc. (NYSE:M)‘s shares dipped -0.30% to $69.90.
Macy’s, Inc. (M) declared that its wholly owned partner, Macy’s Retail Holdings, Inc., will redeem for cash the entire $76.016 million aggregate principal amount outstanding of its 8.125% Debentures due 2035 (CUSIP 577778BC6) on August 17, 2015. The 2035 debentures were issued in August 1995 by The May Department Stores Company and assumed by Macy’s in conjunction with its acquisition of May in August 2005.
The 2035 debentures will be redeemed at par together with interest accrued and unpaid to the redemption date. They become redeemable at 100% of the principal amount thereof at any time on or after August 15, 2015, following the term
Macy’s, Inc., together with its auxiliaries, operates stores and Internet Websites in the United States. Its stores and Websites sell a range of merchandise, counting apparel and accessories for men, women, and children; cosmetics; home furnishings; and other consumer goods. The company also operates Bloomingdale’s Outlet stores that offer a range of apparel and accessories, counting women’s ready-to-wear, fashion accessories, jewelry, handbags, and intimate apparel, in addition to men’s, children’s, and women’s shoes.
Dominion Resources, Inc (NYSE:D), ended its Wednesday’s trading session with 0.13% gain, and closed at $67.65.
California’s Glendale Water & Power (GWP), in collaboration with Dominion Voltage Inc. (DVI), a grid-optimization subsidiary of Dominion Resources (D), has executed a full deployment license agreement for the use of DVI’s EDGE® advanced grid optimization solution.
GWP selected one feeder with about 3,800 electric meters for the pilot. DVI and GWP monitored the system and calculated energy savings from October 2014 through November 2014. The testing validated the predictable energy savings of 2.95 percent, well within the anticipated range of 2-4 percent. This reduction resulted in a savings of 87 megawatt hours (MWh) without requiring a change in customer behavior; when fully deployed, GWP anticipates to save more than 14,500 MWh each year.
EDGE® seamlessly integrates into a utility’s existing IT infrastructure and can obtain voltage readings from the existing AMI system. EDGE® optimizes the utilities’ field devices by issuing commands over an existing wide area network to optimize the distribution system voltage.
Dominion Resources, Inc. produces and transports energy in the United States. The company operates through three segments: Dominion Virginia Power (DVP), Dominion Generation, and Dominion Energy. The DVP segment engages in regulated electric transmission and distribution operations that serve residential, commercial, industrial, and governmental customers in Virginia and North Carolina.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
